W Masmoudi1, M Vaillant2, S Vassileva3, A Patsatsi4, G Quereux5, C Moltrasio6, C Abasq7, C Prost-Squarcioni8, D Kottler9, D Kiritsi10, N Litrowski11, P Plantin12, L Friedrichsen13, A Zebrowska14, S Duvert-Lehembre15, S Hofmann16, V Ferranti1, F Jouen1,2, P Joly1,2, V Hebert1,2. 1. Department of Dermatology, Centre de Référence des Maladies Bulleuses Autoimmunes. 2. Department of Immunology, INSERM U1234, Rouen University Hospital, Rouen, France. 3. Department of Dermatology, Medical University of Sofia, Sofia, Bulgaria. 4. 2nd Department of Dermatology and Venerology, Papageorgiou General Hospital, Aristotle University School of Medicine, Thessaloniki, Greece. 5. Department of Dermatology, Nantes University Hospital, Nantes, France. 6. Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. 7. Department of Dermatology, Brest University Hospital, Brest, France. 8. Department of Dermatology, Avicenne Hospital, University Paris 13, Bobigny, France. 9. Department of Dermatology, Bichat Hospital, AP-HP, Paris, France. 10. Department of Dermatology, Medical Center, University of Freiburg, Freiburg, Germany. 11. Department of Dermatology, Monod General Hospital, Le Havre, France. 12. Department of Dermatology, Centre Hospitalier de Cornouaille, Quimper, France. 13. Department of Dermatology, University of Lubeck, Lubeck, Germany. 14. Department of Dermatology and Venerology, Medical University of Lodz, Lodz, Poland. 15. Department of Dermatology, Lille University Hospital, Lille, France. 16. Department of Dermatology, HELIOS University of Wuppertal, Wuppertal, Germany.
Abstract
BACKGROUND: The Bullous Pemphigoid Disease Area Index (BPDAI) score has been proposed to provide an objective measure of bullous pemphigoid (BP) activity. OBJECTIVES: The objective of this study was to calculate BPDAI cut-off values defining mild, moderate and severe BP. We also aimed to assess the interrater reliability and correlation with the number of daily new blisters, and anti-BP180 and anti-BP230 antibodies. METHODS: Severity scores were recorded by two blinded investigators. Anti-BP180 and anti-BP230 antibodies were measured using an enzyme-linked immunosorbent assay (ELISA). Cut-off values defining mild, moderate and severe subgroups were calculated based on the 25th and 75th percentiles of the BPDAI score. RESULTS: In total, 285 patients with BP were enrolled from 50 dermatology departments in Europe. Median BPDAI activity was 37·5 points (range 0-164). Cut-off values corresponding to the first and third quartiles of the BPDAI score were 20 and 57, respectively; thus, these values were used to define mild (≤ 19), moderate (≥ 20 and ≤ 56) and severe (≥ 57) BP. The median BPDAI score for patients with ≤ 10 daily new blisters was 26 [interquartile range (IQR) 17-45], and for patients with > 10 daily new blisters the median score was 55 (IQR 39-82). The BPDAI intraclass correlation coefficient measured at baseline was 0·97 and remained higher than 0·90 up to month 6. The improvement in the BPDAI score was correlated with the absolute decrease in anti-BP180 ELISA value (Spearman's rank r = 0·34, P < 0·004), but not with anti-BP230 antibodies (r = 0·17, P = 0·15). CONCLUSIONS: This study suggests cut-off values of 20-57 for BPDAI to distinguish mild, moderate and severe BP, and confirms that it is a robust tool to assess BP severity precisely.
BACKGROUND: The Bullous Pemphigoid Disease Area Index (BPDAI) score has been proposed to provide an objective measure of bullous pemphigoid (BP) activity. OBJECTIVES: The objective of this study was to calculate BPDAI cut-off values defining mild, moderate and severe BP. We also aimed to assess the interrater reliability and correlation with the number of daily new blisters, and anti-BP180 and anti-BP230 antibodies. METHODS: Severity scores were recorded by two blinded investigators. Anti-BP180 and anti-BP230 antibodies were measured using an enzyme-linked immunosorbent assay (ELISA). Cut-off values defining mild, moderate and severe subgroups were calculated based on the 25th and 75th percentiles of the BPDAI score. RESULTS: In total, 285 patients with BP were enrolled from 50 dermatology departments in Europe. Median BPDAI activity was 37·5 points (range 0-164). Cut-off values corresponding to the first and third quartiles of the BPDAI score were 20 and 57, respectively; thus, these values were used to define mild (≤ 19), moderate (≥ 20 and ≤ 56) and severe (≥ 57) BP. The median BPDAI score for patients with ≤ 10 daily new blisters was 26 [interquartile range (IQR) 17-45], and for patients with > 10 daily new blisters the median score was 55 (IQR 39-82). The BPDAI intraclass correlation coefficient measured at baseline was 0·97 and remained higher than 0·90 up to month 6. The improvement in the BPDAI score was correlated with the absolute decrease in anti-BP180 ELISA value (Spearman's rank r = 0·34, P < 0·004), but not with anti-BP230 antibodies (r = 0·17, P = 0·15). CONCLUSIONS: This study suggests cut-off values of 20-57 for BPDAI to distinguish mild, moderate and severe BP, and confirms that it is a robust tool to assess BP severity precisely.